Astellas, Theravance Announce European Marketing Authorization For VIBATIV.
Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma, Inc. (ALPMY.PK: News ,ALPMF.PK: News ), and Theravance, Inc. (THRX: News ) announced that the European Commission has granted marketing authorization for VIBATIV (telavancin hydrochloride), following the Committee for Human Medicinal Products' positive opinion in May 2011. VIBATIV is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus, or MRSA.
